Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RBD1016 Phase I in Chronic Hepatitis B
NCT05017116Phase 1Completed
- Sponsor
- Suzhou Ribo Life Science Co., Ltd.
- Start
- Aug 2021
- Primary completion
- Oct 2023
- Modality
- Conjugated siRNA, Small Molecules, Chemically Modified siRNA
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of RBD1016 in Chronic Hepatitis B (CHB) (2 arms), sponsored by Suzhou Ribo Life Science Co., Ltd. Primary endpoint: Adverse events (AEs) and serious adverse events (SAEs) at 28 days. Started Aug 2021; status: completed.
02
Drugs
RBD1016
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NCT05017116.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05017116.